Please login to the form below

Not currently logged in
Email:
Password:

Gilead wins European approval for triple hep C combination Vosevi

The treatment brings together sofosbuvir, velpatasvir and voxilaprevir

GileadGilead Sciences has chalked up a big win with its hepatitis C treatment Vosevi (sofosbuvir/velpatasvir/voxilaprevir) as it becomes the first and only single tablet regimen for patients who have previously failed therapy with direct-acting antivirals (DAA).

The drug was approved to treat adults with genotype 1-6 chronic hepatitis virus (HCV) infection as a 12-week regimen for patients without cirrhosis or with compensated cirrhosis.

Supported by data from two phase III studies, POLARIS-1 and POLARIS-4 evaluated 12 weeks of the single tablet regimen in patients with hepatitis C genotypes 1-6 who were previously treated unsuccessfully with DAA-containing regimens, including NS5A inhibitors.

The results show that 97% of patients on Vosevi achieved the primary efficacy endpoint of a sustained viral response (SVR) for 12 or more weeks post-treatment.

John Milligan, president and chief executive officer, Gilead, said: “The authorisation of Vosevi demonstrates our ongoing commitment to bring therapies with high cure rates to all HCV-infected patients.”

The EC also approved an extension for Harvoni (ledipasvir/sofobuvir), - which was previously authorised to treat adults with chronic HCV genotypes 1, 3, 4, 5, or 6 - and will now include the treatment in adolescents aged 12 to 18 years.

This marks another win for the biopharma as Harvoni is the first DAA chronic HCV treatment to be granted an extension to treat adolescents in the European Union.

Milligan added: “We look forward to working with healthcare providers and government to ensure Vosevi is made available to patients who would benefit the most from it, while continuing to expand the benefits of our other approved medicines for patients with chronic HCV infection across Europe.”

Vosevi has already had the US Food and Drug Administration (FDA) go-ahead back in July for the re-treatment of adults with genotype 1-6 chronic HCV infection.

Article by
Gemma Jones

25th October 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....